BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10726064)

  • 21. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
    Nishiguchi S; Kubo S; Shiomi S
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M; Hamada K; Oda Y; Okuno T
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area.
    Huang YH; Wu JC; Chen CH; Chang TT; Lee PC; Chau GY; Lui WY; Chang FY; Lee SD
    Liver Int; 2005 Apr; 25(2):236-41. PubMed ID: 15780044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
    Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
    Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Tangkijvanich P; Thong-ngam D; Mahachai V; Kladchareon N; Suwangool P; Kullavanijaya P
    Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
    Ohata K; Hamasaki K; Toriyama K; Matsumoto K; Saeki A; Yanagi K; Abiru S; Nakagawa Y; Shigeno M; Miyazoe S; Ichikawa T; Ishikawa H; Nakao K; Eguchi K
    Cancer; 2003 Jun; 97(12):3036-43. PubMed ID: 12784339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of response to treatment in chronic hepatitis C].
    Leroy V; Hilleret MN
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B23-31. PubMed ID: 12180294
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hepatocellular carcinoma: rising incidence of hepatitis C virus-associated cases at a university clinic in Germany].
    Erhardt A; Theobald I; Petry W; Röhrborn A; Heintges T; Wettstein M; Häussinger D
    Dtsch Med Wochenschr; 2002 Dec; 127(50):2665-8. PubMed ID: 12481236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
    Momosaki S; Nakashima Y; Kojiro M; Tabor E
    J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and clinical aspects on hepatitis C.
    Higuchi M; Tanaka E; Kiyosawa K
    Jpn J Infect Dis; 2002 Jun; 55(3):69-77. PubMed ID: 12195046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
    Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
    J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hepatocarcinoma in HCV compensated correlated liver cirrhosis: role of treatment with interferon].
    Testino G
    Recenti Prog Med; 2002 May; 93(5):302-7. PubMed ID: 12050912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
    Vukotic R; Gramenzi A; Vitale G; Cursaro C; Serra C; Biselli M; Scuteri A; Andreone P; Bernardi M
    Liver Int; 2008 Mar; 28(3):407-11. PubMed ID: 17900241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanism and clinical application of carcinogenesis control by IFN].
    Yamamoto T; Nishiguchi S
    Nihon Rinsho; 2006 Jul; 64(7):1254-8. PubMed ID: 16838641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.